Pharmacy benefit management giant Express Scripts unveiled several steps it's taking to boost transparency and mitigate high ...
In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.
"Prime demonstrated how actual patients saved on prescription drugs as a result of the agreement [between Prime and Express Scripts, Inc. ('ESI')]. With this ruling, AHF is seeking to rewind the clock ...
In a recent antitrust arbitration ruling, Prime Therapeutics, a pharmacy benefit manager (PBM) owned by 19 Blue Cross and ...
Evercore ISI has updated its outlook on CVS Health (NYSE:CVS) shares, raising the price target from $60.00 to $65.00 while ...
Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation ...
Arbitrator Stuart Widman found that Prime violated federal and state antitrust laws by engaging in price-fixing agreements with Express Scripts, another major PBM, according to a Jan. 23 news release ...
In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.
An arbitrator has determined Prime Therapeutics violated federal and state antitrust laws against the AIDS Healthcare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback